Sean P Hennessy

University Of Pennsylvania

$26,496,214

Attributed

$33,219,453

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.8M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$32,131,988 · 12

CDC$1,087,465 · 1

By mechanism

R01$24,546,533 · 9

T32$7,030,443 · 2

RC1$1,000,000 · 1

K23$642,477 · 1

Top collaborators

Lang Li12 shared
Vincent Lo Re5 shared
Dylan S Small4 shared
Peter C Adamson2 shared

Others in their field

Top investigators on “Pharmaceutical Preparations”

Sonia M Thomas · Research Triangle Institute$701,865,642
Tracy L Nolen · Research Triangle Institute$474,487,152
David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947

Research focus

Pharmaceutical PreparationsBasePharmacoepidemiologyPersonsDrug InteractionsDrug KineticsElderlyProgramsHealthcareGrantInnovationAffectDesignSeriesProbabilityHospitalizationCytochrome P450BiologicalCohortSimulationLifePharmacologyPublic HealthArea

Grant awards (67)

Clinical Pharmacoepidemiology Training Grant$661,172

T32 · FY2025 · GM · contact PI

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest$739,117

R01 · FY2024 · MH · contact PI

Clinical Pharmacoepidemiology Training Grant$663,867

T32 · FY2024 · GM · contact PI

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest$762,435

R01 · FY2023 · MH · contact PI

Clinical Pharmacoepidemiology Training Grant$625,020

T32 · FY2023 · GM · contact PI

Drug-Drug Interactions Involving Methadone and Buprenorphine$459,352

R01 · FY2023 · DA · contact PI

Stimulant Overdose in the Medicaid Population: Who is at Risk, and When are They at Risk$362,491

R01 · FY2023 · CE · contact PI

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest$679,866

R01 · FY2022 · MH · contact PI

Clinical Pharmacoepidemiology Training Grant$610,802

T32 · FY2022 · GM · contact PI

Enhancing the Utility of the Trend-in-Trend Research Design$564,584

R01 · FY2022 · AG · contact PI

Drug-Drug Interactions Involving Methadone and Buprenorphine$483,741

R01 · FY2022 · DA · contact PI

Stimulant Overdose in the Medicaid Population: Who is at Risk, and When are They at Risk$362,493

R01 · FY2022 · CE · contact PI

Drug-Drug Interactions Involving Methadone and Buprenorphine$647,534

R01 · FY2021 · DA · contact PI

Clinical Importance of Drug-Drug Interactions$628,764

R01 · FY2021 · AG · contact PI

Clinical Pharmacoepidemiology Training Grant$567,627

T32 · FY2021 · GM · contact PI

Enhancing the Utility of the Trend-in-Trend Research Design$561,787

R01 · FY2021 · AG · contact PI

Stimulant Overdose in the Medicaid Population: Who is at Risk, and When are They at Risk$362,481

R01 · FY2021 · CE · contact PI

Clinical Importance of Drug-Drug Interactions$631,712

R01 · FY2020 · AG · contact PI

Drug-Drug Interactions Involving Methadone and Buprenorphine$621,752

R01 · FY2020 · DA · contact PI

Enhancing the Utility of the Trend-in-Trend Research Design$549,226

R01 · FY2020 · AG · contact PI

Clinical Pharmacoepidemiology Training Grant$499,550

T32 · FY2020 · GM · contact PI

Drug-Drug Interactions Involving Methadone and Buprenorphine$679,255

R01 · FY2019 · DA · contact PI

Clinical Importance of Drug-Drug Interactions$591,928

R01 · FY2019 · AG · contact PI

Clinical Pharmacoepidemiology Training Grant$547,721

T32 · FY2019 · GM · contact PI

Enhancing the Utility of the Trend-in-Trend Research Design$531,144

R01 · FY2019 · AG · contact PI

Clinical Importance of Drug-Drug Interactions$635,792

R01 · FY2018 · AG · contact PI

Clinical Pharmacoepidemiology Training Grant$533,439

T32 · FY2018 · GM · contact PI

Clinical Importance of Drug-Drug Interactions$646,786

R01 · FY2017 · AG · contact PI

Drug-Drug Interactions Involving Antidiabetic Agents$581,795

R01 · FY2017 · DK · contact PI

Ambulatory Care Access and Quality$532,162

R01 · FY2017 · HD · contact PI

Clinical Pharmacoepidemiology Training Grant$432,691

T32 · FY2017 · GM · contact PI

Drug-Drug Interactions Involving Antidiabetic Agents$583,142

R01 · FY2016 · DK · contact PI

Ambulatory Care Access and Quality$521,138

R01 · FY2016 · HD · contact PI

Clinical Pharmacoepidemiology Training Grant$426,859

T32 · FY2016 · GM · contact PI

Clinical Importance of Drug-Drug Interactions$399,828

R01 · FY2016 · AG · contact PI

Staging Activity Limitation$294,028

R01 · FY2016 · AG · contact PI

Drug-Drug Interactions Involving Antidiabetic Agents$589,186

R01 · FY2015 · DK · contact PI

Clinical Importance of Drug-Drug Interactions$472,546

R01 · FY2015 · AG · contact PI

Clinical Pharmacoepidemiology Training Grant$259,029

T32 · FY2015 · GM · contact PI

Drug-Drug Interactions Involving Antidiabetic Agents$639,659

R01 · FY2014 · DK · contact PI

Ambulatory Care Access and Quality$517,262

R01 · FY2014 · HD · contact PI

Clinical Importance of Drug-Drug Interactions$471,679

R01 · FY2014 · AG · contact PI

Clinical Pharmacoepidemiology Training Grant$332,043

T32 · FY2014 · GM · contact PI

Pediatric Pharmacoepidemiology Training Program$312,439

T32 · FY2014 · HD

Staging Activity Limitation$300,681

R01 · FY2014 · AG · contact PI

Clinical Importance of Drug-Drug Interactions$506,356

R01 · FY2013 · AG · contact PI

Ambulatory Care Access and Quality$476,603

R01 · FY2013 · HD · contact PI

Pediatric Pharmacoepidemiology Training Program$321,506

T32 · FY2013 · HD

Staging Activity Limitation$296,004

R01 · FY2013 · AG · contact PI

Clinical Pharmacoepidemiology Training Grant$236,678

T32 · FY2013 · GM · contact PI

Clinical Importance of Drug-Drug Interactions$616,899

R01 · FY2012 · AG · contact PI

Data Infrastructure for Post-Marketing Comparative Effectiveness Studies$500,000

RC1 · FY2010 · AG · contact PI

Clinical importance of drug-drug-interactions$473,566

R01 · FY2010 · AG · contact PI

Data Infrastructure for Post-Marketing Comparative Effectiveness Studies$500,000

RC1 · FY2009 · AG · contact PI

Clinical importance of drug-drug interactions$471,517

R01 · FY2009 · AG · contact PI

Drug-Induced sudden death & ventricular arrhythmia$684,723

R01 · FY2008 · HL · contact PI

Clinical Importance of Drug-Drug Interactions$570,837

R01 · FY2008 · AG · contact PI

Drug-Induced sudden death & ventricular arrhythmia$746,946

R01 · FY2007 · HL · contact PI

Clinical Importance of Drug-Drug Interactions$474,107

R01 · FY2007 · AG · contact PI

Drug-Induced sudden death & ventricular arrhythmia$641,760

R01 · FY2006 · HL · contact PI

Clinical importance of drug-drug-interactions$474,388

R01 · FY2006 · AG · contact PI

Drug-Induced sudden death &ventricular arrhythmia$707,481

R01 · FY2005 · HL

RISK FACTORS FOR PHENYTOIN TOXICITY$131,247

K23 · FY2005 · AG

RISK FACTORS FOR PHENYTOIN TOXICITY$131,247

K23 · FY2004 · AG

RISK FACTORS FOR PHENYTOIN TOXICITY$131,247

K23 · FY2003 · AG

RISK FACTORS FOR PHENYTOIN TOXICITY$131,247

K23 · FY2002 · AG

RISK FACTORS FOR PHENYTOIN TOXICITY$117,489

K23 · FY2001 · AG